Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Objectives To investigate associations between daily physical activity, activity intensity and step counts with incident cancer risk. Methods Prospective analysis of UK Biobank participants who wore ...

Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

Analysts forecast explosive growth ahead for AI in healthcare, with MarketsandMarkets projecting the market to surge past $110 billion by 2030 on a 38.6% compound annual growth rate. Accenture goes ...

German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI (Nasdaq: TEM), ...

Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

UPPSALA, SE / ACCESS Newswire / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other Wednesday’s best ...

May 6, 2025Tempus AI, Inc. beats earnings expectations. Reported EPS is $-0.24, expectations were $-0.27. Operator: Good day everyone. And thank you for standing by. My name is Argie, and I will be ...